Who
Oren Gilad
President/CEO
Company insider
Files Form 4 as: President/CEO, Aprea Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 7
- Sells
- 0
- Bought
- $80K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Jul 2022
- Last trade
- 12 Mar 2026
- Last filed
- 16 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,175 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,700 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,700 at $0.00 | filing |
| 12 Mar 2026filed 16 Mar 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,175 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K28,100 at $0.89 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —28,100 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —28,100 | filing |
| 30 Jan 2026filed 2 Feb 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K28,100 at $0.89 | filing |
| 10 Dec 2025filed 11 Dec 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $25K21,459 at $1.17 | filing |
| 10 Dec 2025filed 11 Dec 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —21,459 | filing |
| 3 Apr 2025filed 4 Apr 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,6163,003 at $1.87 | filing |
| 3 Apr 2025filed 4 Apr 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $4,4952,497 at $1.80 | filing |
| 27 Mar 2025filed 31 Mar 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,900 at $0.00 | filing |
| 27 Mar 2025filed 31 Mar 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,725 at $0.00 | filing |
| 23 Oct 2024filed 24 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,960500 at $3.92 | filing |
| 15 Oct 2024filed 16 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $725250 at $2.90 | filing |
| 14 Oct 2024filed 15 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,5901,000 at $2.59 | filing |
| 10 Oct 2024filed 15 Oct 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Bought | $381150 at $2.54 | filing |
| 28 Mar 2024filed 28 Mar 2024 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,900 at $0.00 | filing |
| 28 Mar 2024filed 28 Mar 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,725 at $0.00 | filing |
News
Reviewing Aprea Therapeutics (NASDAQ:APRE) & Oncobiologics (NASDAQ:OTLK)APRE · themarketsdaily.com · 20 Oct 2026Reviewing Aprea Therapeutics (NASDAQ:APRE) & CRISPR Therapeutics (NASDAQ:CRSP)APRE · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Oren Gilad; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.